New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

14

Angion ends kidney disease trial while Novo hits NASH wall

Shares of Angion Biomedica Corp. are falling fast after the company announced it had discontinued a mid-stage study of an oral tyrone kinase inhibitor in patients with primary proteinuric kidney diseases due to safety reasons. And Novo Nordisk also hit a wall, reporting that its diabetes drug Ozempic (semaglutide) failed to inprove liver fibrosis in NASH-related cirrhosis.

19

Top 3 Pandemic-Related Health IT Technologies and What to Expect

Providers continue to adapt to the new care models to patients’ needs. As the pandemic wreaked havoc across the United States, healthcare providers started deploying various health IT solutions to address emerging challenges. They aimed to reduce the load on doctors and protect clinicians and patients from the virus exposure.